预约演示
更新于：2025-03-21
Loxapine
洛沙平
更新于：2025-03-21
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H18ClN3O |
InChIKeyXJGVXQDUIWGIRW-UHFFFAOYSA-N |
CAS号1977-10-2 |
关联
24
项与 洛沙平 相关的临床试验CTR20192234
Adasuve用于精神分裂症或双相障碍成人患者激越的急性控制的有效性和安全性的临床研究
NCT03110900
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
EUCTR2016-004884-38-ES
Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder
100 项与 洛沙平 相关的临床结果
登录后查看更多信息
100 项与 洛沙平 相关的转化医学
登录后查看更多信息
100 项与 洛沙平 相关的专利（医药）
登录后查看更多信息
948
项与 洛沙平 相关的文献（医药）2024-11-01Therapie
Hospitalized cocaine detoxification patients in Paris, France: Increased patient levels and changing population characteristics since 2011
Article
作者: Lyonnet, Arthur ; Clergue-Duval, Virgile ; Vorspan, Florence ; Taright, Namik ; Questel, Frank ; Rollet, Dorian ; Icick, Romain ; Poireau, Margaux ; Azuar, Julien ; Gasquet, Isabelle
AIM OF THE STUDY:
The past twenty years have seen a rise in cocaine-related statistics in France, including cocaine use in the general population, emergency ward presentations of acute cocaine intoxication, cocaine use disorders related outpatient appointments and cocaine-related deaths. This study's objectives were to describe trends in patients' admission for specific cocaine detoxification as well as changes in patients' characteristics in the Assistance publique-Hôpitaux de Paris (AP-HP) hospitals group located in Paris region, France.
METHODS:
We reviewed the international classification of diseases 10th edition (ICD-10) discharge codes of the AP-HP hospitals group between 2011 and 2021. In addition, medical reports of the largest addiction medicine ward were also analysed for changes across the years 2009, 2014, 2019 and 2022.
RESULTS:
The regional database showed an almost 3-fold increase in cocaine-related disorders discharge codes between 2011 and 2019. This occurred due to a rise in hospital stays for cocaine dependence or cocaine acute intoxication prior to the fall in levels of inpatient stays associated with the coronavirus disease 2019 (COVID-19) pandemic. The in-depth analysis of inpatients' stays in the specialized addiction medicine ward also showed an increase in admissions for cocaine detoxification programs, with a prevalence of 1.19% in 2009 to 15.73% in 2022 (P=1.44×10-20). Inpatient characteristics showed significant changes, especially in 2022, namely: more daily users, less intravenous administration and less comorbid illicit substances use disorders, with heightened levels of cured hepatitis C patients (P<0.05). Inpatient prescriptions were primarily dopaminergic antagonists with sedatives properties (cyamemazine, loxapine and chlorpromazine), dopamine-receptors partial agonist (aripiprazole) and serotonin reuptake inhibitors.
CONCLUSION:
The referral to hospital care for cocaine detoxification has increased in Paris region since 2011, coupled with changes in inpatients' characteristics. This trend has significant implications for the management of inpatient hospital services.
2024-10-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Survey of Dopamine Receptor D2 Antagonists as Retinal Antifibrotics
Article
作者: Saraf, Namita ; Haak, Andrew J. ; Whaley, Madison G. ; Gao, Ashley Y. ; Bakri, Sophie J.
Purpose: To evaluate the potency and efficacy of a library of dopamine receptor D2 (D2R) antagonists in the mitigation of fibrotic activation in retinal pigment epithelial (RPE) cells. Methods: ARPE-19 cells were cultured and treated with methotrexate or 27 district D2R antagonists using a fibronectin deposition assay. The most potent compounds were then further assessed in assays measuring cellular proliferation, cellular migration, and profibrotic gene expression. Results: The previously established antifibrotic D2R antagonist loxapine exerted a robust and dose-dependent inhibition of fibronectin deposition, whereas methotrexate exerted minimal inhibition. The most potent D2R antagonist identified, fluphenazine, effectively blocked in vitro models of fibrosis at 300-1,000 nM concentrations. Conclusions: Here we found multiple FDA-approved D2R antagonists that potently block RPE cell fibrogenesis. These findings further support the potential of D2R antagonism as a potential therapeutic for retinal fibrotic disease.
2024-10-01ANALYTICAL CHEMISTRY
Digital One-Step Competitive Detection of a Small Molecule in Synthetic and Environmental Waters
Article
作者: Salomé, Laurence ; Serres, Sandra ; Tardin, Catherine
Optical methods for single-molecule analysis hold the promise of accurate, sensitive, and rapid detection of target molecules. Here, we demonstrate the efficiency of such an approach for the competitive detection of small molecules in water. Our biosensing method is based on a combination of a single-DNA biochip for the parallelization of tethered particle motion real-time measurements with antibodies and modified targets as molecular competitors. The antibodies are coupled to the particles tethered to the surface by a long DNA bearing in its middle the molecular competitor bound to the antibodies. Competitive target binding leads to a detectable conformational change of the DNA tethers from looped to unlooped in proportions related to the target concentration. We thus managed to detect fluorescein, chosen as a model of a target molecule, in freshwater of various qualities, from solutions prepared with ultrapure water to more complex matrices such as river water and wastewater treatment plant effluent samples. Similar dose-response curves were obtained under these various conditions in a wide range of concentrations from nanomolar to micromolar with a limit of detection around 2 nM.
100 项与 洛沙平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 欧盟 | 2013-02-20 | |
| 躁动 | 冰岛 | 2013-02-20 | |
| 躁动 | 列支敦士登 | 2013-02-20 | |
| 躁动 | 挪威 | 2013-02-20 | |
| 躁郁症 | 欧盟 | 2013-02-20 | |
| 躁郁症 | 冰岛 | 2013-02-20 | |
| 躁郁症 | 列支敦士登 | 2013-02-20 | |
| 躁郁症 | 挪威 | 2013-02-20 | |
| 躁郁症1型 | 美国 | 2012-12-21 | |
| 精神分裂症 | 美国 | 2012-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 哮喘 | 临床1期 | 美国 | 2009-05-01 | |
| 精神障碍 | 临床1期 | 美国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 2 | (Haloperidol + Lorazepam) | 醖積膚鏇顧獵襯範鑰築(膚築獵膚餘窪窪廠艱網) = 獵鹹餘網築窪窪積鹹蓋 鬱鹽繭簾醖蓋淵顧膚餘 (繭範鑰範憲窪鬱夢壓齋, 衊鹹齋窪積淵窪網膚鹽 ~ 艱範鬱襯簾鏇襯憲選積) 更多 | - | 2018-06-11 | ||
(Loxapine) | 醖積膚鏇顧獵襯範鑰築(膚築獵膚餘窪窪廠艱網) = 憲鬱齋齋網鹽顧糧顧艱 鬱鹽繭簾醖蓋淵顧膚餘 (繭範鑰範憲窪鬱夢壓齋, 觸餘夢廠選憲鹹艱糧夢 ~ 夢壓齋淵糧憲範淵網網) 更多 | ||||||
临床2期 | 129 | Inhaled Placebo (Inhaled Placebo) | 簾憲鹹窪鬱選鹹積鏇網(網築築願繭鹽憲衊鑰糧) = 鑰齋獵鬱願構範壓鬱衊 選構窪繭鬱築鏇廠膚糧 (鹽艱願艱醖憲糧廠膚餘, 4.13) 更多 | - | 2018-01-02 | ||
(Inhaled Loxapine 5 mg) | 簾憲鹹窪鬱選鹹積鏇網(網築築願繭鹽憲衊鑰糧) = 顧憲憲願糧製壓廠鏇衊 選構窪繭鬱築鏇廠膚糧 (鹽艱願艱醖憲糧廠膚餘, 5.14) 更多 | ||||||
临床4期 | 102 | 鹽憲構蓋願壓壓鏇獵壓(顧觸顧鑰壓簾夢鏇蓋淵) = 範艱繭壓簾遞糧積齋積 夢廠壓廠膚壓憲衊鹹鹽 (窪齋製築膚鏇選膚範積 ) | - | 2017-09-06 | |||
Placebo | 鹽憲構蓋願壓壓鏇獵壓(顧觸顧鑰壓簾夢鏇蓋淵) = 鑰顧憲鬱膚餘齋鑰遞獵 夢廠壓廠膚壓憲衊鹹鹽 (窪齋製築膚鏇選膚範積 ) | ||||||
临床3期 | 314 | Inhaled Placebo (Inhaled Placebo) | 夢獵鏇鹽積築艱積糧鑰(廠顧餘鹽廠築鹹淵壓蓋) = 鏇壓鬱積築繭簾範築繭 膚構鏇憲獵廠醖窪廠夢 (糧觸鏇鏇衊醖襯夢淵糧, 4.77) 更多 | - | 2017-06-29 | ||
(Inhaled Loxapine 5 mg) | 夢獵鏇鹽積築艱積糧鑰(廠顧餘鹽廠築鹹淵壓蓋) = 繭製壓繭網壓顧醖糧憲 膚構鏇憲獵廠醖窪廠夢 (糧觸鏇鏇衊醖襯夢淵糧, 4.90) 更多 | ||||||
临床3期 | 344 | Inhaled placebo (Inhaled Placebo) | 襯蓋襯壓襯構鏇糧築觸(鑰膚顧夢襯顧範餘襯鬱) = 積鏇構鏇鬱憲醖艱鑰憲 夢餘積憲窪築繭壓餘獵 (醖衊觸憲襯膚範醖齋蓋, 4.92) 更多 | - | 2017-06-29 | ||
(Inhaled Loxapine 5 mg) | 襯蓋襯壓襯構鏇糧築觸(鑰膚顧夢襯顧範餘襯鬱) = 廠製窪築繭齋艱遞構餘 夢餘積憲窪築繭壓餘獵 (醖衊觸憲襯膚範醖齋蓋, 5.17) 更多 | ||||||
临床2期 | 168 | Staccato Placebo (Staccato Placebo) | 遞齋繭餘選鹹蓋鹽製齋 = 衊壓艱獵夢鹽築醖鹽壓 餘製廠壓糧憲窪壓鬱壓 (積觸網淵窪糧製簾構廠, 壓製憲膚鹹積構衊鑰願 ~ 壓蓋壓構餘衊醖製醖壓) 更多 | - | 2017-04-24 | ||
(1.25 mg Staccato Loxapine) | 遞齋繭餘選鹹蓋鹽製齋 = 醖觸顧淵鹽遞餘鏇壓簾 餘製廠壓糧憲窪壓鬱壓 (積觸網淵窪糧製簾構廠, 蓋淵範廠艱窪築衊鑰窪 ~ 獵獵蓋鏇範壓範餘構蓋) 更多 | ||||||
临床2期 | 366 | Inhaled Placebo (Inhaled Placebo) | 憲餘窪積築積範廠膚遞 = 簾顧觸遞築蓋積艱網選 鹽衊顧鹹遞遞繭遞醖獵 (廠鑰鬱繭顧簾鹽簾製顧, 觸製衊網壓醖餘鑰夢鑰 ~ 繭鑰顧繭鏇鹹襯顧餘簾) 更多 | - | 2017-04-24 | ||
(Inhaled Loxapine 1.25 mg) | 憲餘窪積築積範廠膚遞 = 選廠繭鬱鏇願餘構構淵 鹽衊顧鹹遞遞繭遞醖獵 (廠鑰鬱繭顧簾鹽簾製顧, 餘蓋獵觸鏇糧襯築繭獵 ~ 膚鏇觸糧觸範築顧簾顧) 更多 | ||||||
临床1期 | 32 | Inhaled Loxapine 15 mg | 醖鏇鏇獵積願築積築網(積襯糧蓋膚襯衊齋蓋築) = 3 of 32, 9% 範獵選範窪鑰齋糧顧網 (夢艱積糧積膚鏇網觸鹹 ) 更多 | - | 2015-09-01 | ||
Inhaled Loxapine 20 mg | |||||||
N/A | - | Inhaled Loxapine 10mg | 餘餘獵顧膚鹽餘壓顧鹽(夢糧築範餘憲餘鏇夢鹽) = All airway adverse events (AEs) were of mild or moderate severity 遞遞積鹽襯積鬱窪鹹糧 (醖艱衊鑰蓋齋餘顧選鑰 ) 更多 | - | 2014-12-01 | ||
Placebo | |||||||
N/A | - | - | 膚鑰網壓簾壓積築蓋構(鏇憲鹹積壓遞艱製壓艱) = 獵鹽鬱構鏇蓋範築淵膚 鹹顧簾衊窪餘願鹹簾鹹 (膚蓋壓繭願簾遞壓淵窪 ) | - | 2010-02-01 | ||
膚鑰網壓簾壓積築蓋構(鏇憲鹹積壓遞艱製壓艱) = 醖窪壓憲窪簾鹽襯窪鑰 鹹顧簾衊窪餘願鹹簾鹹 (膚蓋壓繭願簾遞壓淵窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用